Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Eisai Stories

2012-10-25 09:20:04

Tokyo, Oct 25, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has signed a global agreement with Brazil's Fundacao Oswaldo Cruz ("Fiocruz") aimed at collaborations to develop new medicines and vaccines for malaria and neglected tropical diseases (NTDs).Under the global agreement, Eisai and Fiocruz will identify research development collaborations targeting Eisai compounds for indications of malaria and NTDs. For the first collaboration, it has been decided to begin studies on...

2012-10-22 19:21:07

WOODCLIFF LAKE, N.J., Oct. 22, 2012 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA (perampanel) as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy age 12 and older. FYCOMPA is the first FDA-approved non-competitive AMPA glutamate receptor antagonist. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO) "The FDA approval of FYCOMPA is an...

2012-10-03 02:28:03

ANNAPOLIS, Md., and WOODCLIFF LAKE, N.J., Oct. 3, 2012 /PRNewswire/ -- METAvivor Research and Support, Inc. and Eisai Inc. announced today the launch of "The Elephant in the Pink Room," a campaign designed to place a spotlight on metastatic breast cancer (MBC), a form of the disease that causes nearly 40,000 deaths per year and is often ignored, particularly during Breast Cancer Awareness Month in October. (Photo: http://photos.prnewswire.com/prnh/20121003/NY83368 ) Approximately...

2012-09-25 04:20:08

Tokyo, Sept 25, 2012 - (JCN Newswire) - Eisai Co., Ltd. and Santen Pharmaceutical Co., Ltd. announced today that they have entered into an option agreement which grants Santen rights of evaluation and first negotiation for Eisai-owned compounds in the field of ophthalmology.Under the terms of the agreement, Eisai shall grant Santen the rights to evaluate the feasibility of developing compounds disclosed by Eisai for use in the ophthalmologic field within a certain period as well as the rights...

2012-09-17 02:25:45

GREENSBORO, N.C., Sept. 17, 2012 /PRNewswire/ -- Merz, Inc. (U.S. affiliate of Merz Pharma Group) today announced the appointment of Cynthia Schwalm has as vice president, neurology effective immediately. Schwalm will be responsible for the Merz's growing neurology business unit in the U.S., which includes the recently acquired product CUVPOSA(®). "Cynthia brings national as well as international experience, in developing and commercializing pharmaceutical products. We are extremely...

2012-09-12 04:20:07

Tokyo, Sept 12, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a partnership agreement to supply the Sabin Vaccine Institute (Headquarters: Washington D.C., President: Dr. Peter Hotez, "Sabin") with E6020, an in-house developed adjuvant that enhances the immune effects of vaccines, as well as all relevant information pertaining to the compound free of charge, to support the development of vaccines for two neglected tropical diseases (NTDs) - Chagas disease...

2012-09-12 04:20:02

Tokyo, Sept 12, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch Crystal Veil(R) alpha (classified as miscellaneous goods), a drug-free topical nasal gel that utilizes positively charged ions to help block viruses from entering the body through the nose, on Tuesday, September 18.Crystal Veil alpha is a positively-charged gel that helps prevent virus particles, which are even smaller than pollen, from entering through the nose. It is the third product in the Crystal...

2012-09-11 04:20:06

Tokyo, Sept 11, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the anti-rheumatic agent Careram(R) (iguratimod) in Japan on September 12 for the treatment of rheumatoid arthritis. Careram, jointly developed in Japan by Eisai and Toyama Chemical Co., Ltd. from the Phase III clinical development stage, was approved by Japan's Ministry of Health, Labour and Welfare (MHLW) in June of this year and was subsequently listed on the National Health Insurance Drug Price...

2012-08-27 02:25:49

EXTON, Pa., Aug. 27, 2012 /PRNewswire/ -- Morphotek(®), Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 when combined with gemcitabine and docetaxel in the treatment of metastatic soft tissue sarcoma. MORAb-004 is a monoclonal antibody that specifically binds to endosialin/tumor endothelial marker-1 (TEM-1). MORAb-004 is thought to function as an inhibitor of the tumor microenvironment. TEM-1 is thought to play...

2012-08-20 06:25:54

WOODCLIFF LAKE, N.J., Aug. 20, 2012 /PRNewswire/ -- Eisai Inc. announced today that the results of two studies: "Evaluation of Adjunctive Perampanel in Patients with Refractory Partial Onset Seizures: Results of Randomized Global Phase III Study 305," and "Perampanel, A Selective, Non-Competitive AMPA Receptor Antagonist, as Adjunctive Therapy for Refractory Partial-Onset Seizures: Interim Results from Phase III, Open-Label Extension Study 307," were published today in the online publication...